Encompass Health director buys 284 shares

A separate 20-RSU award was credited in connection with the October 15 common-stock dividend, while the larger share entry reflects quarterly fee deferrals.

Rhea-AI Filing Summary

Encompass Health Corp director Christopher R. Reidy acquired 284 common shares on October 19, 2026, at a weighted average price of $126.89 per share. The shares were purchased through the Directors Deferred Stock Investment Plan using quarterly fee deferrals and the $0.21-per-share dividend paid October 15; purchase prices ranged from $126.83 to $126.89. On October 15, Reidy also received an award of 20 restricted stock units credited in connection with the dividend.

Insider Trade Summary

Grant/Award: 304 shares

Grant/Award 2 txns

Insider Reidy Christopher R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock F2, F3	284	$126.89	$36K
Grant/Award	Encompass Health Common Stock F1	20	$0.00	$0.00

Holdings After Transaction: Encompass Health Common Stock — 18,081 shares (Direct)

Footnotes (3)

1. F1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.
2. F2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.21 per share paid on October 15, 2026.
3. F3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.83 to $126.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

Key Figures

Common shares acquired: 284 shares Weighted average price: $126.89 per share Purchase price range: $126.83 to $126.89 per share +3 more

6 metrics

Common shares acquired 284 shares October 19, 2026; Directors Deferred Stock Investment Plan

Weighted average price $126.89 per share 284 shares acquired October 19, 2026

Purchase price range $126.83 to $126.89 per share Multiple transactions for the October 19, 2026 share acquisition

Restricted stock units awarded 20 RSUs Credited October 15, 2026, in connection with the common-stock dividend

Common-stock dividend $0.21 per share Paid October 15, 2026

Closing price $127.77 October 15, 2026

Key Terms

restricted stock units ("RSUs"), Directors Deferred Stock Investment Plan, non-qualified deferral plan, weighted average price

4 terms

restricted stock units ("RSUs") financial

"additional restricted stock units ("RSUs") are credited"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Directors Deferred Stock Investment Plan financial

"The Directors Deferred Stock Investment Plan of the Company"

non-qualified deferral plan financial

"is a non-qualified deferral plan adopted and approved"

weighted average price financial

"This per share price is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EHC shares did Christopher R. Reidy acquire?

Christopher R. Reidy acquired 284 common shares on October 19, 2026, at a weighted average price of $126.89 per share. The shares were purchased in multiple transactions at prices ranging from $126.83 to $126.89 through the Directors Deferred Stock Investment Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 03:42 PM EDT Accepted by SEC EDGAR 10/19/2026 - 03:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reidy Christopher R

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM ALABAMA 35242

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	10/15/2026		A		20(1)	A	$0	17,797	D
Encompass Health Common Stock	10/19/2026		A		284(2)	A	$126.89(3)	18,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2026, Encompass Health paid a dividend on its common stock of $0.21 per share and the closing price was $127.77. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.

2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.21 per share paid on October 15, 2026.

3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.83 to $126.89, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

Remarks:

	/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)